Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Silibinin is a novel and ancient molecule that highlights the significance of integrated therapies for cancer.

2.

Does diabetes impact the prognosis of people with colorectal cancer?

3.

Q&A: When will individuals be able to receive customized cancer vaccines?

4.

Alkem introduces cetuximab under the trade name Cetuxa in India.

5.

Researchers can now forecast how prostate cancer bone metastases will react to radium-223 treatment.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot